ClinicalTrials.gg
Active, not recruitingNCT05270525Updated Nov 3, 2026

Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)

A Phase 2 interventional study of Ensifentrine and Placebo in Pulmonary Disease, Chronic Obstructive, COPD, sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA. Active, not recruiting at 3 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Primary conditionPulmonary Disease, Chronic ObstructiveRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Disease, Chronic Obstructive
Why
  1. The study's listed conditions name Pulmonary Disease, Chronic Obstructive, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Nov 3, 2026Now Active, not recruitingEnrollment updated+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.

Enrollment
9th of 15
70 · median 79
Started
2022
the only one that year
Phase 2
8 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
3 of 15
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 8 in phase 2, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ensifentrine

ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat chronic obstructive pulmonary disease (COPD). COPD is a long-lasting swelling of the airways that makes it hard to breathe. Researchers want to learn if a trial medicine called ensifentrine can help treat sputum caused by COPD. In this trial, researchers will compare a trial medicine called ensifentrine to a placebo. A placebo looks like the trial medicine but has no medicine in it. Using a placebo helps researchers better understand the effects of a trial medicine.

The goal of this trial is to learn about the effect of ensifentrine on a substance found in mucus (sputum) from the lungs that may be a sign of inflammation in participants with COPD.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive, COPD

Browse trials for

04

In context

Pulmonary Disease, Chronic Obstructive Reclassified

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

This study's enrollment of 70 is above the median of 62 across 3,844 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted before Verona Pharma plc became part of Merck & Co., Inc.

Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a history of cigarette smoking ≥10 pack years and an established clinical history of (COPD) as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD. Number of pack-years = [number of cigarettes per day/20] × number of years smoked [e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]
  • COPD Severity: Pre- and Post-albuterol/salbutamol /Forced vital capacity (FEV1/FVC) ratio of \<0.70; Post-albuterol/salbutamol FEV1 ≥30 % and ≤80% of predicted normal calculated using the National Health and Nutrition Examination Survey III
  • Regular use of bronchodilator COPD therapy, in any form (e.g., [Long-acting muscarinic antagonist] LAMA, [Long-acting β2-agonist] LABA, LAMA+LABA, LAMA+LABA+ [Inhaled (s)] ICS), for at least 4 weeks prior to Screening and agrees to use study supplied COPD Maintenance Therapy once daily through the final study visit
  • Capable of using the jet nebulizer correctly and complying with all study restrictions and procedures
  • Ability to perform acceptable spirometry in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines
  • Ability to produce sputum samples during the induced sputum procedure

Exclusion criteria

Exclusion Criteria:

  • Any clinically diagnosed lung disease other than such as current asthma, diffuse interstitial lung diseases, cystic fibrosis, or bronchiectasis as determined by the Investigator
  • Hospitalizations for COPD exacerbation, pneumonia, or other respiratory infection in the 12 weeks prior to Screening.
  • (ALT) ≥ 2 x (ULN), alkaline phosphatase and/or > 1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
  • (HIV) infection or other immunodeficiency
  • History of cancer within the last 5 years, except for well-treated basal cell carcinoma and squamous cell carcinoma of the skin
  • Any clinically significant 12-lead abnormalities at screening or baseline, including interval by Fridericia's correction method >450 ms for males or >480 ms for females or history of significant cardiac dysrhythmia, including long QT syndrome
  • Known history of poor outcomes with sputum induction
  • Known to ensifentrine or other medications used in the study (e.g., albuterol or salmeterol)
  • Not suitable for study supplied once daily COPD Maintenance Therapy per label warnings and
  • Taking prohibited medication
  • Prior receipt of Ohtuvayre or blinded nebulized study medication in an ensifentrine (RPL554) study. Note: Other ensifentrine formats (e.g., DPI, MPI) are not exclusionary
  • Use of an experimental drug within 30 days or 5 half-lives of Screening, whichever is longer, and/or participation in a study treatment-free follow-up phase of a clinical trial within 30 days prior to Screening
  • Use of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical trial within 30 days prior to Screening
  • Any other medical history, chronic uncontrolled diseases that the investigator considers clinically significant, examination or laboratory findings or reason that the Investigator considers makes the patient unsuitable to participate at Screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Ensifentrine Sequence 1

    In treatment period 1 participants will receive 3 mg ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks followed by treatment period 2 during which participants will receive placebo matching ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks. Throughout treatment sequence 1 participants will receive LABA/LAMA background therapy.

    Drug: Ensifentrine · Drug: Placebo · Drug: LABA/LAMA

  • Experimental
    Ensifentrine Sequence 2

    In treatment period 1 participants will receive placebo matching ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks followed by treatment period 2 during which participants will receive 3 mg ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks. Throughout treatment sequence 2 participants will receive LABA/LAMA background therapy.

    Drug: Ensifentrine · Drug: Placebo · Drug: LABA/LAMA

Interventions

  • Ensifentrine administered twice daily by oral inhalation via a standard jet nebulizer.

  • DrugPlacebo

    Placebo matching ensifentrine administered twice daily by oral inhalation via a standard jet nebulizer.

  • DrugLABA/LAMA

    Background treatment of LAMA/LABA administered per product approved label delivered by oral inhalation.

    Also known as: Anoro®

07

What researchers measure

Primary outcomes

  1. The Absolute Change From Baseline in Sputum Neutrophil Cell Numbers

    The Absolute change from baseline in sputum neutrophil cell numbers will be reported.

    Time frame: Baseline and 8 Weeks

Secondary outcomes

  1. Absolute Change in Cell Numbers From Baseline in Sputum Cell Counts

    Absolute change in cell numbers from baseline in sputum cell counts (eosinophils, basophils, macrophages, lymphocytes, total cells) will be reported.

    Time frame: Baseline and 8 Weeks

  2. Percent Change From Baseline in Sputum Cell Counts

    Percent change from baseline in sputum cell counts (neutrophils, eosinophils, basophils, macrophages, lymphocytes, and total cells) will be reported.

    Time frame: Baseline and 8 Weeks

  3. Percent Change From Baseline in Cytokines

    Percent Change From Baseline in Cytokines will be reported.

    Time frame: Baseline and 8 Weeks

  4. Percent Change From Baseline in Proteases

    Percent Change From Baseline in Proteases will be reported.

    Time frame: Baseline and 8 Weeks

  5. Percent Change From Baseline in Markers of Inflammation

    Percent Change From Baseline in Markers of Inflammation will be reported.

    Time frame: Baseline and 8 Weeks

  6. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 4 Weeks

    Change from baseline in FEV1 at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.

    Time frame: Baseline and 4 Weeks

  7. Change From Baseline in FEV1 at 8 Weeks

    Change from baseline in FEV1 at 8 weeks during the treatment period (postdose) will be reported.

    Time frame: Baseline and 8 Weeks

  8. Change From Baseline in Forced Vital Capacity (FVC) at 4 Weeks

    Change from baseline in FVC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.

    Time frame: Baseline and 4 Weeks

  9. Change From Baseline in FVC at 8 Weeks

    Change from baseline in FVC at 8 weeks during the treatment period (postdose) will be reported.

    Time frame: Baseline and 8 Weeks

  10. Change From Baseline in Residual Volume (RV) at 4 Weeks

    Change from baseline in RV at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.

    Time frame: Baseline and 4 Weeks

  11. Change From Baseline in RV at 8 Weeks

    Change from baseline in RV at 8 weeks (postdose) during the treatment period will be reported.

    Time frame: Baseline and 8 Weeks

  12. Change From Baseline in Functional Residual Capacity (FRC) at 4 Weeks

    Change from baseline in FRC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.

    Time frame: Baseline and 4 Weeks

  13. Change From Baseline in FRC at 8 Weeks

    Change from baseline in FRC at 8 weeks (postdose) during the treatment period will be reported.

    Time frame: Baseline and 8 Weeks

  14. Change From Baseline in Total Lung Capacity (TLC) at 4 Weeks

    Change from baseline in TLC at 4 weeks during the treatment period (predose and 2 hours postdose) will be reported.

    Time frame: Baseline and 4 Weeks

  15. Change From Baseline in TLC at 8 Weeks

    Change from baseline in TLC at 8 weeks (postdose) during the treatment period will be reported.

    Time frame: Baseline and 8 Weeks

  16. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Number of participants who experience one or more adverse events will be reported.

    Time frame: Up to approximately 8 Weeks

  17. Change From Baseline in Systolic Blood Pressure

    Change from baseline in systolic blood pressure will be reported.

    Time frame: Baseline and 8 Weeks

  18. Change From Baseline in Diastolic Blood Pressure

    Change from baseline in diastolic blood pressure will be reported.

    Time frame: Baseline and 8 Weeks

  19. Change From Baseline in Heart Rate

    Change from baseline in heart rate will be reported.

    Time frame: Baseline and 8 Weeks

  20. Change From Baseline in QRS Duration

    Change from baseline in QRS duration will be reported.

    Time frame: Baseline and 8 Weeks

  21. Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)

    Change from baseline in QTcF will be reported.

    Time frame: Baseline and 8 Weeks

  22. Change From Baseline in QT Interval

    Change from baseline for in QT interval will be reported.

    Time frame: Baseline and 8 Weeks

Other outcomes

  1. Change From Baseline in Absolute Blood Cell Counts at 4 Weeks

    Change from baseline in absolute blood cell counts at 4 weeks will be reported.

    Time frame: Baseline and 4 Weeks

  2. Change From Baseline in Cytokines at 4 Weeks

    Change From Baseline in Cytokines at 4 Weeks will be reported.

    Time frame: Baseline and 4 Weeks

  3. Change From Baseline in Proteases at 4 Weeks

    Change From Baseline in Proteases at 4 Weeks will be reported.

    Time frame: Baseline and 4 Weeks

  4. Change From Baseline in Markers of Inflammation at 4 Weeks

    Change From Baseline in Markers of Inflammation at 4 Weeks will be reported.

    Time frame: Baseline and 4 Weeks

  5. Change From Baseline in Absolute Blood Cell Counts at 8 Weeks

    Change from baseline in absolute blood cell counts at 8 weeks will be reported.

    Time frame: Baseline and 8 Weeks

  6. Change From Baseline in Cytokines at 8 Weeks

    Change from baseline in cytokines at 8 weeks will be reported.

    Time frame: Baseline and 8 Weeks

  7. Change From Baseline in Proteases at 8 Weeks

    Change from baseline in proteases at 8 weeks will be reported.

    Time frame: Baseline and 8 Weeks

  8. Change From Baseline in Blood Markers of Inflammation at 8 Weeks

    Change from baseline in blood markers of inflammation at 8 weeks will be reported.

    Time frame: Baseline and 8 Weeks

  9. Percent Change From Baseline in Sputum Acetylated Proline-Glycine-Proline (AcPGP) at 8 Weeks

    Percent change from baseline in sputum Acetylated Proline-Glycine-Proline (AcPGP) at 8 weeks will be reported.

    Time frame: Baseline and 8 Weeks

  10. Percent Change From Baseline in Sputum Proline-Glycine-Proline (PGP) at 8 Weeks

    Percent change from baseline in sputum PGP at 8 weeks will be reported.

    Time frame: Baseline and 8 Weeks

08

Study locations

3 sites
09

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Mar 2027, 57 months after the start.

Of 119 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 57 months is above that.

Counting every sponsor, half of 166 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2026 → Mar 2027 and completion Jun 2027 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Mar 8, 2022
StartActual
May 27, 2022
Primary completionEst.
Mar 1, 2027was Dec 2026
CompletionEst.
Mar 1, 2027was Jun 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 30, 2026
Primary completion
Dec 2026→Mar 1, 2027
Sep 30, 2026
Study completion
Jun 2027→Mar 1, 2027
Sep 30, 2026
Enrollment
56 (estimated)→70 (actual)
Nov 3, 2026
Eligibility
4 inclusion criteria edited, 2 added; 4 exclusion criteria edited, 9 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedMale and female patients 40-80 years of ageParticipants with a history of cigarette smoking ≥10 pack years and an established clinical history of chronic obstructive pulmonary disease (COPD) as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD. Number of pack-years = [number of cigarettes per day/20] × number of years smoked [e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]
  • EditedCOPD Severity: Pre- and Post-albuterol/salbutamol Forced expiratory volume in 1 second/Forced vital capacity (FEV1/FVC) ratio of <0.70; Post-albuterol/salbutamol FEV1 ≥30 % and ≤80% of predicted normal calculated using the National Health and Nutrition Examination Survey III.
  • EditedRegular use of bronchodilator COPD therapy, in any form (e.g., [Long-acting muscarinic antagonist] LAMA, [Long-acting β2-agonist] LABA, LAMA+LABA, LAMA+LABA+ [Inhaled corticosteroid(s)] ICS), for at least 4 weeks prior to Screening and agrees to use study supplied COPD Maintenance Therapy once daily through the final study visit.
  • EditedCapable of using the jet nebulizer correctly and complying with all study restrictions and procedures. Ability to perform acceptable spirometry in accordance with ATS/ERS guidelines. Ability to produce sputum samples during the induced sputum procedure.
  • AddedAbility to perform acceptable spirometry in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines
  • AddedAbility to produce sputum samples during the induced sputum procedure
Exclusion criteria
  • RemovedAny clinically diagnosed lung disease other than COPD such as current asthma, diffuse interstitial lung diseases, cystic fibrosis, or clinically significant bronchiectasis as determined by the Investigator. Hospitalizations for COPD, pneumonia, or Corona Virus Disease 2019 (COVID-19) in the 12 weeks prior to Screening; or a positive COVID-19 test result indicating an active infection at Screening.*Note: Patients with a positive COVID-19 antibody test from a past exposure who do not exhibit symptoms of an active COVID-19 infection are eligible to participate in the study. *A COVID-19 test may be performed at the visit or within 7 days prior to the visit (or as required locally). Asymptomatic patients with a positive COVID-19 test result indicating an active infection < 30 days prior to Screening or at Screening may be re-screened for eligibility after 30 days (or in accordance with local requirements).
  • AddedAny clinically diagnosed lung disease other than COPD such as current asthma, diffuse interstitial lung diseases, cystic fibrosis, or clinically significant bronchiectasis as determined by the Investigator
  • AddedHospitalizations for COPD exacerbation, pneumonia, or other respiratory infection in the 12 weeks prior to Screening.
  • EditedAlanine aminotransferase (ALT) ≥ 2 x upper limit of normal (ULN), alkaline phosphatase and/or bilirubin > 1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). HIV infection or other immunodeficiency. History of cancer within the last 5 years, except for well-treated basal cell carcinoma and squamous cell carcinoma of the skin.
  • AddedHuman immunodeficiency virus (HIV) infection or other immunodeficiency
  • AddedHistory of cancer within the last 5 years, except for well-treated basal cell carcinoma and squamous cell carcinoma of the skin
  • AddedKnown history of poor outcomes with sputum induction
  • EditedKnown history of poor outcomes with sputum induction. Known hypersensitivity to ensifentrine or other medications used in the study (e.g., albuterol or salmeterol). Not suitable for study supplied once daily COPD Maintenance Therapy per label warnings and contraindications.
  • AddedNot suitable for study supplied once daily COPD Maintenance Therapy per label warnings and contraindications
  • AddedTaking prohibited medication
  • EditedTaking prohibited medication. Prior receipt of Ohtuvayre or blinded nebulized study medication in an ensifentrine (RPL554) study. Note: Other ensifentrine formats (e.g., DPI, MPI) are not exclusionary.
  • EditedUse of an experimental drug within 30 days or 5 half-lives of Screening, whichever is longer, and/or participation in a study treatment-free follow-up phase of a clinical trial within 30 days prior to Screening. Use of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical trial within 30 days prior to Screening. Any other medical history, chronic uncontrolled diseases that the investigator considers clinically significant, examination or laboratory findings or reason that the Investigator considers makes the patient unsuitable to participate at Screening.
  • AddedUse of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical trial within 30 days prior to Screening
  • AddedAny other medical history, chronic uncontrolled diseases that the investigator considers clinically significant, examination or laboratory findings or reason that the Investigator considers makes the patient unsuitable to participate at Screening
Nov 3, 2026
Interventions
Added Drug: LABA/LAMA. Arm changed Treatment Sequence 1→Ensifentrine Sequence 1; Treatment Sequence 2→Ensifentrine Sequence 2
Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedThe change from baselineAbsolute Change From Baseline in sputum neutrophils at Week 8 (absolute change in cell numbers)Sputum Neutrophil Cell NumbersTime frame: Week 8 → Baseline and 8 Weeks
Nov 3, 2026
Secondary outcomes
17 edited, 13 added, 3 more
What changed in the outcomes
  • EditedThe change from baselinePercent Change From Baseline in sputum cell counts at Week 8 (absolute change in cell numbers)Sputum Cell CountsTime frame: Week 8 → Baseline and 8 Weeks
  • EditedThe percent change from baselineAbsolute Change in sputum cell counts at Week 8Cell Numbers From Baseline in Sputum Cell CountsTime frame: Week 8 → Baseline and 8 Weeks
  • EditedThe percent change from baselinePercent Change From Baseline in sputum markers of inflammation at Week 8CytokinesTime frame: Week 8 → Baseline and 8 Weeks
  • EditedThe change from baselinePercent Change From Baseline in FEV1 after 4 weeksProteasesTime frame: Week 4 → Baseline and 8 Weeks
  • EditedThe change from baselineChange From Baseline in FEV1 afterat 8 weeks (post-dose)WeeksTime frame: Week 8 → Baseline and 8 Weeks
  • EditedThe change from baselineChange From Baseline in Forced Vital Capacity (FVC after) at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
  • EditedThe change from baselineChange From Baseline in FVC afterat 8 weeks (post-dose)WeeksTime frame: Week 8 → Baseline and 8 Weeks
  • EditedThe change from baselineChange From Baseline in Residual Volume (RV after) at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
  • EditedThe change from baselineChange From Baseline in RV afterat 8 weeks (post-dose)WeeksTime frame: Week 8 → Baseline and 8 Weeks
  • EditedThe change from baselineChange From Baseline in Functional Residual Capacity (FRC after) at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
  • EditedThe change from baselineChange From Baseline in FRC afterat 8 weeks (post-dose).WeeksTime frame: Week 8 → Baseline and 8 Weeks
  • EditedThe change from baselineChange From Baseline in Total Lung Capacity (TLC after) at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
  • EditedThe change from baselineChange From Baseline in TLC afterat 8 weeks (post-dose)WeeksTime frame: Week 8 → Baseline and 8 Weeks
  • AddedPercent Change From Baseline in Markers of InflammationTime frame: Baseline and 8 Weeks
  • AddedChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 4 WeeksTime frame: Baseline and 4 Weeks
  • AddedNumber of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 8 Weeks
  • AddedChange From Baseline in Systolic Blood PressureTime frame: Baseline and 8 Weeks
  • AddedChange From Baseline in Diastolic Blood PressureTime frame: Baseline and 8 Weeks
  • AddedChange From Baseline in Heart RateTime frame: Baseline and 8 Weeks
  • AddedChange From Baseline in QRS DurationTime frame: Baseline and 8 Weeks
  • AddedChange From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)Time frame: Baseline and 8 Weeks
  • AddedChange From Baseline in QT IntervalTime frame: Baseline and 8 Weeks
  • Editedother outcomeExploratory: change from baselineChange From Baseline in blood markers of inflammation afterAbsolute Blood Cell Counts at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
  • Editedother outcomeExploratory: change from baselineChange From Baseline in blood markers of inflammation after 8 weeksCytokines at 4 WeeksTime frame: Week 8 → Baseline and 4 Weeks
  • Editedother outcomeExploratory: The percent change from baselineChange From Baseline in sputum AcPGPProteases at week 84 WeeksTime frame: Week 8 → Baseline and 4 Weeks
  • Editedother outcomeExploratory: The percent change from baselineChange From Baseline in sputum PGPAbsolute Blood Cell Counts at week 88 WeeksTime frame: Week 8 → Baseline and 8 Weeks
  • Addedother outcomeChange From Baseline in Markers of Inflammation at 4 WeeksTime frame: Baseline and 4 Weeks
  • Addedother outcomeChange From Baseline in Cytokines at 8 WeeksTime frame: Baseline and 8 Weeks
  • Addedother outcomeChange From Baseline in Proteases at 8 WeeksTime frame: Baseline and 8 Weeks
  • Addedother outcomeChange From Baseline in Blood Markers of Inflammation at 8 WeeksTime frame: Baseline and 8 Weeks
  • …and 3 more, on the record history on ClinicalTrials.gov ↗
Nov 3, 2026
Title
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD→Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Enrollment 56 (estimated)→70 (actual)
    Eligibility 4 inclusion criteria edited, 2 added; 4 exclusion criteria edited, 9 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedMale and female patients 40-80 years of ageParticipants with a history of cigarette smoking ≥10 pack years and an established clinical history of chronic obstructive pulmonary disease (COPD) as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD. Number of pack-years = [number of cigarettes per day/20] × number of years smoked [e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years]
    • EditedCOPD Severity: Pre- and Post-albuterol/salbutamol Forced expiratory volume in 1 second/Forced vital capacity (FEV1/FVC) ratio of <0.70; Post-albuterol/salbutamol FEV1 ≥30 % and ≤80% of predicted normal calculated using the National Health and Nutrition Examination Survey III.
    • EditedRegular use of bronchodilator COPD therapy, in any form (e.g., [Long-acting muscarinic antagonist] LAMA, [Long-acting β2-agonist] LABA, LAMA+LABA, LAMA+LABA+ [Inhaled corticosteroid(s)] ICS), for at least 4 weeks prior to Screening and agrees to use study supplied COPD Maintenance Therapy once daily through the final study visit.
    • EditedCapable of using the jet nebulizer correctly and complying with all study restrictions and procedures. Ability to perform acceptable spirometry in accordance with ATS/ERS guidelines. Ability to produce sputum samples during the induced sputum procedure.
    • AddedAbility to perform acceptable spirometry in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines
    • AddedAbility to produce sputum samples during the induced sputum procedure
    Exclusion criteria
    • RemovedAny clinically diagnosed lung disease other than COPD such as current asthma, diffuse interstitial lung diseases, cystic fibrosis, or clinically significant bronchiectasis as determined by the Investigator. Hospitalizations for COPD, pneumonia, or Corona Virus Disease 2019 (COVID-19) in the 12 weeks prior to Screening; or a positive COVID-19 test result indicating an active infection at Screening.*Note: Patients with a positive COVID-19 antibody test from a past exposure who do not exhibit symptoms of an active COVID-19 infection are eligible to participate in the study. *A COVID-19 test may be performed at the visit or within 7 days prior to the visit (or as required locally). Asymptomatic patients with a positive COVID-19 test result indicating an active infection < 30 days prior to Screening or at Screening may be re-screened for eligibility after 30 days (or in accordance with local requirements).
    • AddedAny clinically diagnosed lung disease other than COPD such as current asthma, diffuse interstitial lung diseases, cystic fibrosis, or clinically significant bronchiectasis as determined by the Investigator
    • AddedHospitalizations for COPD exacerbation, pneumonia, or other respiratory infection in the 12 weeks prior to Screening.
    • EditedAlanine aminotransferase (ALT) ≥ 2 x upper limit of normal (ULN), alkaline phosphatase and/or bilirubin > 1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). HIV infection or other immunodeficiency. History of cancer within the last 5 years, except for well-treated basal cell carcinoma and squamous cell carcinoma of the skin.
    • AddedHuman immunodeficiency virus (HIV) infection or other immunodeficiency
    • AddedHistory of cancer within the last 5 years, except for well-treated basal cell carcinoma and squamous cell carcinoma of the skin
    • AddedKnown history of poor outcomes with sputum induction
    • EditedKnown history of poor outcomes with sputum induction. Known hypersensitivity to ensifentrine or other medications used in the study (e.g., albuterol or salmeterol). Not suitable for study supplied once daily COPD Maintenance Therapy per label warnings and contraindications.
    • AddedNot suitable for study supplied once daily COPD Maintenance Therapy per label warnings and contraindications
    • AddedTaking prohibited medication
    • EditedTaking prohibited medication. Prior receipt of Ohtuvayre or blinded nebulized study medication in an ensifentrine (RPL554) study. Note: Other ensifentrine formats (e.g., DPI, MPI) are not exclusionary.
    • EditedUse of an experimental drug within 30 days or 5 half-lives of Screening, whichever is longer, and/or participation in a study treatment-free follow-up phase of a clinical trial within 30 days prior to Screening. Use of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical trial within 30 days prior to Screening. Any other medical history, chronic uncontrolled diseases that the investigator considers clinically significant, examination or laboratory findings or reason that the Investigator considers makes the patient unsuitable to participate at Screening.
    • AddedUse of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical trial within 30 days prior to Screening
    • AddedAny other medical history, chronic uncontrolled diseases that the investigator considers clinically significant, examination or laboratory findings or reason that the Investigator considers makes the patient unsuitable to participate at Screening
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedThe change from baselineAbsolute Change From Baseline in sputum neutrophils at Week 8 (absolute change in cell numbers)Sputum Neutrophil Cell NumbersTime frame: Week 8 → Baseline and 8 Weeks
    Secondary outcomes 17 edited, 13 added, 3 more
    What changed in the outcomes
    • EditedThe change from baselinePercent Change From Baseline in sputum cell counts at Week 8 (absolute change in cell numbers)Sputum Cell CountsTime frame: Week 8 → Baseline and 8 Weeks
    • EditedThe percent change from baselineAbsolute Change in sputum cell counts at Week 8Cell Numbers From Baseline in Sputum Cell CountsTime frame: Week 8 → Baseline and 8 Weeks
    • EditedThe percent change from baselinePercent Change From Baseline in sputum markers of inflammation at Week 8CytokinesTime frame: Week 8 → Baseline and 8 Weeks
    • EditedThe change from baselinePercent Change From Baseline in FEV1 after 4 weeksProteasesTime frame: Week 4 → Baseline and 8 Weeks
    • EditedThe change from baselineChange From Baseline in FEV1 afterat 8 weeks (post-dose)WeeksTime frame: Week 8 → Baseline and 8 Weeks
    • EditedThe change from baselineChange From Baseline in Forced Vital Capacity (FVC after) at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
    • EditedThe change from baselineChange From Baseline in FVC afterat 8 weeks (post-dose)WeeksTime frame: Week 8 → Baseline and 8 Weeks
    • EditedThe change from baselineChange From Baseline in Residual Volume (RV after) at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
    • EditedThe change from baselineChange From Baseline in RV afterat 8 weeks (post-dose)WeeksTime frame: Week 8 → Baseline and 8 Weeks
    • EditedThe change from baselineChange From Baseline in Functional Residual Capacity (FRC after) at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
    • EditedThe change from baselineChange From Baseline in FRC afterat 8 weeks (post-dose).WeeksTime frame: Week 8 → Baseline and 8 Weeks
    • EditedThe change from baselineChange From Baseline in Total Lung Capacity (TLC after) at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
    • EditedThe change from baselineChange From Baseline in TLC afterat 8 weeks (post-dose)WeeksTime frame: Week 8 → Baseline and 8 Weeks
    • AddedPercent Change From Baseline in Markers of InflammationTime frame: Baseline and 8 Weeks
    • AddedChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 4 WeeksTime frame: Baseline and 4 Weeks
    • AddedNumber of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 8 Weeks
    • AddedChange From Baseline in Systolic Blood PressureTime frame: Baseline and 8 Weeks
    • AddedChange From Baseline in Diastolic Blood PressureTime frame: Baseline and 8 Weeks
    • AddedChange From Baseline in Heart RateTime frame: Baseline and 8 Weeks
    • AddedChange From Baseline in QRS DurationTime frame: Baseline and 8 Weeks
    • AddedChange From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)Time frame: Baseline and 8 Weeks
    • AddedChange From Baseline in QT IntervalTime frame: Baseline and 8 Weeks
    • Editedother outcomeExploratory: change from baselineChange From Baseline in blood markers of inflammation afterAbsolute Blood Cell Counts at 4 weeksWeeksTime frame: Week 4 → Baseline and 4 Weeks
    • Editedother outcomeExploratory: change from baselineChange From Baseline in blood markers of inflammation after 8 weeksCytokines at 4 WeeksTime frame: Week 8 → Baseline and 4 Weeks
    • Editedother outcomeExploratory: The percent change from baselineChange From Baseline in sputum AcPGPProteases at week 84 WeeksTime frame: Week 8 → Baseline and 4 Weeks
    • Editedother outcomeExploratory: The percent change from baselineChange From Baseline in sputum PGPAbsolute Blood Cell Counts at week 88 WeeksTime frame: Week 8 → Baseline and 8 Weeks
    • Addedother outcomeChange From Baseline in Markers of Inflammation at 4 WeeksTime frame: Baseline and 4 Weeks
    • Addedother outcomeChange From Baseline in Cytokines at 8 WeeksTime frame: Baseline and 8 Weeks
    • Addedother outcomeChange From Baseline in Proteases at 8 WeeksTime frame: Baseline and 8 Weeks
    • Addedother outcomeChange From Baseline in Blood Markers of Inflammation at 8 WeeksTime frame: Baseline and 8 Weeks
    • …and 3 more, on the record history on ClinicalTrials.gov ↗
    Interventions Added Drug: LABA/LAMA. Arm changed Treatment Sequence 1→Ensifentrine Sequence 1; Treatment Sequence 2→Ensifentrine Sequence 2
    Title Effect of Ensifentrine on Sputum Markers of Inflammation in COPD→Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
    + 6 other changes: verification date, description, conditions, design details, contact details and index terms
  2. Sep 30, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 2026→Mar 1, 2027
    Study completion Jun 2027→Mar 1, 2027
    + 6 other changes: identifiers, verification date, contact details, site details, data sharing statement and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05270525
Responsible party
Sponsor
First posted
Mar 8, 2022
Start date
May 27, 2022
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensifentrine

Start the discussion